This page shows the details of why an item matched the keywords from your search.
| Item Type | Name |
|
Concept
|
Vaccines, Subunit
|
|
Academic Article
|
Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines.
|
|
Academic Article
|
Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
|
|
Academic Article
|
Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
|
|
Academic Article
|
Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer.
|
|
Academic Article
|
Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
|
|
Academic Article
|
The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
|
|
Academic Article
|
Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04.
|
|
Academic Article
|
The E75 HER2/neu peptide vaccine.
|
|
Academic Article
|
Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
|
|
Academic Article
|
Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer.
|
|
Academic Article
|
Adjuvant HER2/neu peptide cancer vaccines in breast cancer.
|
|
Academic Article
|
The development and use of the E75 (HER2 369-377) peptide vaccine.
|
|
Academic Article
|
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence.
|
|
Academic Article
|
Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.
|
|
Academic Article
|
Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response.
|
|
Academic Article
|
Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design.
|
|
Academic Article
|
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.
|
|
Academic Article
|
Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ.
|